Efficacy of oxybutynin, pseudoephedrine and indomethacin in the treatment of primary nocturnal enuresis.
The efficacy of oxybutynin, pseudoephedrine and indomethacin treatment was investigated in 29 patients with primary nocturnal enuresis. Patients were randomly assigned to either oxybutynin (1st group, n = 9), pseudoephedrine (2nd group, n = 11) or indomethacin (3rd group, n = 9) treatments. Oxybutynin and indomethacin did not cause a statistically significant difference in the number of dry nights (p > 0.05), but patients treated with pseudoephedrine had a significant increase in the number of dry nights (p < 0.05). Five patients in the oxybutynin and one patient in the indomethacin group experienced side effects. None of the patients in the pseudoephedrine group had any complaints with the drug. We therefore conclude that pseudoephedrine can be an alternative in the treatment of primary nocturnal enuresis.
Varan
B
B
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara.
Saatçi
U
U
Ozen
S
S
Bakkaloğlu
A
A
Beşbaş
N
N
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004775:Enuresis / Q000188:drug therapy* / Q000652:urine; D004809:Ephedrine / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008333:Mandelic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D018680:Cholinergic Antagonists; D016861:Cyclooxygenase Inhibitors; D008333:Mandelic Acids; D004809:Ephedrine; C005419:oxybutynin; D007213:Indomethacin